On October 29, 2026, X4 Pharmaceuticals filed an 8-K to post its Virtual Investor Day presentation on its website. The filing provides no new financial or operational data beyond the scheduled event. X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing mavorixafor for rare hematology diseases.
